---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Conclusions"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Conclusions. 1 evidence topic quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary/conclusions"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Conclusions

<a id="heading-1.1.4"></a>

## 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

### Summary

- Tumor hyperinsulinism comprises insulinoma, with a population-based incidence of 0.6 to 4 cases per million per year in the studies identified, and non-islet cell tumor hypoglycemia, for which no population-based estimate exists. Survival is reduced in metastatic or malignant insulinoma (median 3.4 years with metastases in a Finnish nationwide cohort), and refractory hypoglycemia in these patients is associated with prolonged hospitalization and deferral of tumor-directed therapy.
- Current therapies have documented limitations: surgery is curative for most localized insulinomas but carries operative morbidity, diazoxide and somatostatin analogs control hypoglycemia in a proportion of patients with insulinoma and are described as ineffective in NICTH, and tumor-directed therapies for malignant disease do not directly treat hypoglycemia according to the manufacturer.
- The efficacy evidence for ersodetug in tumor hyperinsulinism consists of preliminary, unpublished results from the single-arm, open-label upLIFT trial (13 responders among 16 participants, with at least 9 required for statistical significance; final results pending) and a retrospective case series of 8 individuals with no control group. The randomized sunRIZE trial in congenital hyperinsulinism did not meet its primary or key secondary endpoint.
- The safety data come mostly from the congenital hyperinsulinism trials and include serious hypersensitivity reactions (overall incidence approximately 2% across the clinical trials) and hypertrichosis (about 35% of ersodetug-treated sunRIZE participants). No drug-related serious adverse events were reported in the tumor hyperinsulinism case series or, to date, in upLIFT.
- Ersodetug is investigational, with a biologics license application planned for mid-2027, and has no price; no budget impact model or economic evaluation has been published.

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/); [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/); [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/); [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/); [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/); [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm); [Howe et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7029300/); [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm); [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism); [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism); [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
